Hans-Peter Kiem, M.D., Ph.D., is currently the Fred Hutch Endowed Chair for Cell and Gene Therapy, Associate Head, Program in Transplantation Biology, Member, Clinical Research Division, Fred Hutchinson, Professor of Medicine / Adjunct Professor of Pathology University of Washington School of Medicine and Associate Head, Heme Malignancy Program, UW / Fred Hutchinson Cancer Consortium.
Dr. Kiem has an extensive background working in pre-clinical and clinical studies involving stem cell biology, including induced pluripotent stem cells, hematopoietic stem cell transplantation and gene therapy. His research focus has been the study of stem cell biology and cell engineering with applications involving genetic and infectious diseases and cancer. Dr. Kiem is the sponsor of four clinical stem cell gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and is the PI or Co-PI of many R01 or P01 grants, including a Martin Delaney Consortium grant to study HIV cure strategies (defeatHIV). He also serves as the Chair of the NIH Recombinant DNA Advisory Committee (RAC), the American Society for Gene and Cell Therapy (ASGCT) Stem Cell Committee, and the ASH (American Society of Hematology) Stem Cell and Regenerative Medicine Committee. Dr. Kiem holds an M.D. and Ph.D. from the University of Ulm in Germany. As a research fellow at Stanford University, he studied molecular abnormalities and minimal residual in patients with lymphoma and the use of a novel immunodeficient mouse model for lymphoma. Dr. Kiem completed his residency in Internal Medicine and his Physician/Scientist training at Vanderbilt University. He then joined the Fred Hutchinson Cancer Research Center, where he completed his clinical fellowship in Oncology.